从纵向测序中识别胶质瘤进化的预测因子
本研究收集544例成人弥漫性胶质瘤初发-复发配对肿瘤的测序与临床数据,通过多变量分析识别三种弥漫性胶质瘤亚型中肿瘤进化的早期分子预测因子,并构建机器学习模型CELLO2预测治疗后超突变与进展,进一步在细胞系和患者来源胶质瘤球中证实MYC通过促进超突变驱动替莫唑胺耐药。
要点
- 初诊时CDKN2A缺失先于IDH突变型胶质瘤晚期出现的肿瘤坏死和微血管增生。
- 初诊时MYC扩增或MYC靶基因激活与复发时治疗诱导的超突变相关。
- CELLO2模型可分层预后并识别MYC扩增的高危患者组,其进展后生存更差。
核心结论
- 本研究揭示了治疗下癌症进化的早期预测因子,并为靶向弥漫性胶质瘤癌症动态的精准肿瘤学提供了资源。
研究设计与样本
- 收集544例成人弥漫性胶质瘤初发-复发配对肿瘤的测序与临床数据,进行多变量分析以识别三种弥漫性胶质瘤亚型中肿瘤进化的早期分子预测因子。
- 构建整合初诊特征的机器学习模型CELLO2,用于预测治疗后超突变和进展。
- 在胶质瘤细胞系和同基因患者来源胶质瘤球中进行慢性替莫唑胺诱导实验。
主要发现
- 初诊时CDKN2A缺失先于IDH突变型胶质瘤晚期发生的肿瘤坏死和微血管增生。
- 初诊时Ki67表达与IDH野生型胶质瘤复发时获得性超突变呈正相关。
- 在所有胶质瘤亚型中,初诊时MYC扩增或MYC靶基因激活与复发时治疗诱导的超突变相关。
- CELLO2成功将患者分层为预后不同的亚组,并从低级别IDH突变非共缺失亚型中识别出以MYC扩增为特征、进展后生存更差的高危患者组。
- 慢性替莫唑胺诱导实验表明MYC通过促进超突变驱动替莫唑胺耐药;机制上c-MYC结合开放染色质和转录活跃基因组区域,增加关键错配修复基因对治疗诱导突变的易感性,从而触发超突变。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A deletion at initial diagnosis preceded tumor necrosis and microvascular proliferation that occur at later stages of IDH-mutant glioma. Ki67 expression at diagnosis was positively correlated with acquiring hypermutation at recurrence in the IDH-wild-type glioma. In all glioma subtypes, MYC gain or MYC-target activation at diagnosis was associated with treatment-induced hypermutation at recurrence. To predict glioma evolution, we constructed CELLO2 (Cancer EvoLution for LOngitudinal data version 2), a machine learning model integrating features at diagnosis to forecast hypermutation and progression after treatment. CELLO2 successfully stratified patients into subgroups with distinct prognoses and identified a high-risk patient group featured by MYC gain with worse post-progression survival, from the low-grade IDH-mutant-noncodel subtype. We then performed chronic temozolomide-induction experiments in glioma cell lines and isogenic patient-derived gliomaspheres and demonstrated that MYC drives temozolomide resistance by promoting hypermutation. Mechanistically, we demonstrated that, by binding to open chromatin and transcriptionally active genomic regions, c-MYC increases the vulnerability of key mismatch repair genes to treatment-induced mutagenesis, thus triggering hypermutation. This study reveals early predictors of cancer evolution under therapy and provides a resource for precision oncology targeting cancer dynamics in diffuse gliomas.
引用
- Mu Q, Chai R, Pang B, et al. Identifying predictors of glioma evolution from longitudinal sequencing. Sci Transl Med. 2023. PMID: 37792958. doi:10.1126/scitranslmed.adh4181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。